Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences
Bull Case

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

• The stock is currently trading at $150.93, which is below the consensus price target of $158.78, suggesting potential upside for investors as analysts maintain a Moderate Buy rating.
• Gilead Sciences, Inc. recently expanded access to its HIV prevention drug lenacapavir across 120 high-incidence countries through royalty-free voluntary licensing, signaling strong global demand and strategic growth in its core virology franchise.
• The company reported Q2 2026 revenue of $7.80 billion, beating the consensus estimate of $7.40 billion, demonstrating robust top-line growth of 10.6% year-over-year despite a net loss.
• With a beta of 0.33, Gilead Sciences, Inc. exhibits lower volatility than the broader market, offering a defensive characteristic that may appeal to investors seeking stability in the healthcare sector.
• The company maintains a dividend yield of 2.15%, providing a steady income stream for shareholders, with the most recent quarterly dividend of $0.82 per share paid on September 29, 2026.